Testing of nasal delivery devices
Optimal testing of nasal delivery devices requires
equipment that allows full control over parameters
and provides traceable data at each step. Astech has
established inhaler testing solutions and continues to
advance automation technology for device testing.
Each element of our inhaled testing equipment comes
with Relovex
®
, our intuitive 21 CFR Part 11 compli-
ant software, allowing ease of use and fully traceable
results throughout for data integrity requirements.
Astech o ers exible systems to automate your nasal
drug delivery testing process from start to nish.
Astech Projects
UK: +44 1928 571797
www.astechprojects.co.uk
Breath-actuated nebulizers
Vectura's state-of-the-art breath-actuated nebuliz-
ers, with guided inhalation, have been developed to
improve lung delivery for inhaled drugs, with the aim
of achieving better clinical outcomes and/or shortened
treatment times. e basis of the smart nebulization
technology is to tailor the e cient delivery of the aero-
sol within the lungs, in terms of ow rate, volume and
timing during inhalation, to the individual patient's
breathing capacity and pattern.
Vectura
UK: +44 1249 667700
www.vectura.com
Glass expansion chambers
Quantif y the amount of drug in small particles/
droplets of nasal sprays and the particle/droplet size
distribution of nasal aerosols with Copley's range of
glass expansion chambers. Designed to meet FDA
draft guidance, chambers are available for both nasal
sprays (2 liters) and nasal aerosols (5 liters). Specialized
adapters and clamps are also available to interface the
glass expansion chambers with your cascade impactor.
Copley Scienti c
UK: +44 1159 616229
www.copleyscienti c.com
Soft mist inhaler
e Merxin MR X004 is a soft mist inhaler device,
developed as an interchangeable device opportunity
for tiotropium/olodaterol, as formulated with the
Respimat
®
inhaler. e MRX004 can be ideal for life
cycle management and new molecules, particularly
for those products that could bene t from a reduced
dose and deep lung penetration. It does not require
a propellant or electric power. e MR X004 is also
environmentally friendly and can provide high IP
protection. It is being evaluated with new molecules
including potential COVID-19 treatments, and can
be used to repurpose existing molecules, for life cycle
management, and to reformulate molecules from neb-
ulizers, pMDIs or DPIs.
Merxin
UK: +44 1553 403070
www.merxin.com
20 JUNE 2020 Inhalation
